Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors

References

• Pollen JJ, Gerber K, Ashburn WL, Schmidt JD. Nuclear bone imaging in metastatic cancer of the prostate. Cancer 1981; 47: 2585–94
   PubMed Web of Science ®Google Scholar
• Gerber G, Chodak GW. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology 1991; 37: 418–22
   PubMed Web of Science ®Google Scholar
• Terris MK, Klonecke AS, McDougall IR, Stamey TA. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 1991; 32: 1713–7
   PubMed Web of Science ®Google Scholar
• Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195–202
   PubMed Web of Science ®Google Scholar
• Imai K, Tomaru Y, Ohnuki T, Yamanaka H, Sakai H, Kanetake H, et al. Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate carcinoma with bone metastasis. Cancer 1992; 69: 2983–9
   PubMed Web of Science ®Google Scholar
• Palmberg C, Koivisto P, Visakorpi T, Tammela TL. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol 1999; 36: 191–6
   PubMed Web of Science ®Google Scholar
• Mikkola, A, Aro, J, Rannikko, S, Ruutu, M, Finnprostate Group. Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy. Prostate 2007;67:447–55.
   PubMed Web of Science ®Google Scholar
• Johansson, JE, Andersson, SO, Holmberg, L, Bergstrom, R. Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. J Urol 1991;146:1327–32; Discussion 1332–3.
   PubMed Web of Science ®Google Scholar
• Johansson JE, Sigurdsson T, Holmberg L, Bergstrom R. Erythrocyte sedimentation rate as a tumor marker in human prostatic cancer. An analysis of prognostic factors in 300 population-based consecutive cases. Cancer 1992; 70: 1556–63
   PubMed Web of Science ®Google Scholar
• Evans CP, Gajendran V, Tewari A, Aslam K, Juster R, Gange S, et al. The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate. Br J Urol 1996; 78: 426–31
   PubMedGoogle Scholar
• Gronberg H, Damber L, Jonson H, Damber JE. Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age. Urology 1997; 49: 374–8
   PubMed Web of Science ®Google Scholar
• Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997; 20: 605–8
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Soloway MS, Van der Zwaag R, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989; 141: 1139–42
   PubMed Web of Science ®Google Scholar
• Mulders PF, Dijkman GA, Fernandez del Moral P, Theeuwes AG, Debruyne FM. Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. Cancer 1990; 65: 2758–61
   PubMed Web of Science ®Google Scholar
• Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 1991; 265: 618–21
   PubMed Web of Science ®Google Scholar
• Reynard JM, Peters TJ, Gillatt D. Prostate-specific antigen and prognosis in patients with metastatic prostate cancer – a multivariable analysis of prostate cancer mortality. Br J Urol 1995; 75: 507–15
   PubMedGoogle Scholar
• Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1998; 33: 134–43
   PubMed Web of Science ®Google Scholar
• Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169: 164–9
   PubMed Web of Science ®Google Scholar
• Shimbo M, Suzuki H, Kamiya N, Imamoto T, Komiya A, Ueda T, et al. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer. Eur Urol 2005; 47: 557–63
   PubMed Web of Science ®Google Scholar
• de Reijke, T, Derobert, E, Anandron/Nilutamide Study Group. Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. Eur Urol 2002;42:139–46.
   PubMed Web of Science ®Google Scholar
• Jorgensen T, Kanagasingam Y, Kaalhus O, Tveter KJ, Bryne M, Skjorten F, et al. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2. J Urol 1997; 158: 164–70
   PubMed Web of Science ®Google Scholar
• Smith JA, Jr, Lange PH, Janknegt RA, Abbou CC, deGery A. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol 1997; 157: 1329–34
   PubMed Web of Science ®Google Scholar
• Rainwater LM, Morgan WR, Klee GG, Zincke H. Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma. Mayo Clin Proc 1990; 65: 1118–26
   PubMed Web of Science ®Google Scholar
• Mikkola AK, Aro JL, Rannikko SA, Salo JO. Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. Finnprostate Group. Prostate 1999; 39: 175–81
   PubMed Web of Science ®Google Scholar
• Mikkola AK, Ruutu ML, Aro JL, Rannikko SA, Salo JO. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. Br J Urol 1998; 82: 63–8
   PubMedGoogle Scholar
• Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008; 42: 220–9
   PubMedGoogle Scholar
• Kuoppasalmi K. Plasma testosterone and sex-hormone-binding globulin capacity in physical exercise. Scand J Clin Lab Invest 1980; 40: 411–8
   PubMed Web of Science ®Google Scholar
• Adlercreutz H, Fotsis T, Heikkinen R. Current state of the art in the analysis of estrogens. Advances in steroid analysis, S Görög. Akadémiai Kiadó, Budapest 1982; 3–33
   Google Scholar
• Rannikko S, Kairento AL, Karonen SL, Adlercreutz H. Hormonal pattern in prostatic cancer. I. Correlation with local extent of tumour, presence of metastases and grade of differentiation. Acta Endocrinol (Copenh) 1981; 98: 625–33
   PubMedGoogle Scholar
• Horder M, Gerhardt W, Harkonen M, Magid E, Pitkanen E, Stromme JH, et al. Experiences with the Scandinavian recommended methods for determinations of enzymes in blood. A report by the Scandinavian Committee on Enzymes (SCE). Scand J Clin Lab Invest 1981; 41: 107–16
   PubMed Web of Science ®Google Scholar
• Bishop MC, Hardy JG, Taylor MC, Wastie ML, Lemberger RJ. Bone imaging and serum phosphatases in prostatic carcinoma. Br J Urol 1985; 57: 317–24
   PubMedGoogle Scholar
• Lande, K, Rustad, P, Steensland, H, Strömme, J, Theodorsen, L, Urdal, P. Suggested reference intervals for 8 serum enzymes based on data from the NORIP database. http://www.furst.no/norip/reports/enz.htm. Updated 24 September 2003, accessed 16 April 2008.
   Google Scholar
• Dacie, JU, Lewis, SM. Practical haematology8th ed. Hong Kong: Churchill Livingstone; 1995. p 12–14.
   Google Scholar
• Imai K, Suzuki T, Kobayashi M, Yamanaka H, Tomaru Y, Sato J. The significance of erythrocyte sedimentation rate as a prognostic factor for patients with prostate cancer: Gunma Urological Oncology Study Group investigation. Jpn J Cancer Res 1990; 81: 971–4
   PubMedGoogle Scholar